Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emil Novruzov

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
PET Clinics|April 7, 2023
The Diagnostic Value of Fibroblast Activation Protein Imaging in Hepatocellular Carcinoma and Cholangiocellular CarcinomaEmil Novruzov, Yuriko Mori, Fuad Novruzov
PET Clinics|April 29, 2025
Applications of Fibroblast Activation Protein Inhibitor-PET in Interventional OncologyYuriko Mori, Emil Novruzov, Frederik L Giesel, et al.
Seminars in Nuclear Medicine|July 19, 2025
The Clinical Impact of FAPI PET Imaging: HCC, CCC, CUP & Peritoneal CarcinomaEmil Novruzov, Eduards Mamlins, Yuriko Mori, et al.
Hellenic Journal of Nuclear Medicine|April 19, 2026
An auxiliary <sup>18</sup>F-FDG uptake pattern clarifying equivocal adrenal gland mass after dual-tracer imaging with <sup>123</sup>I-mIBG SPECT/CT and <sup>18</sup>F-FDG PET/CTEmil Novruzov, Sandra Jaschinski, Irene Esposito, et al.
Seminars in Nuclear Medicine|July 8, 2022
A Role of Non-FDG Tracers in Lung Cancer?Emil Novruzov, Yuriko Mori, Christina Antke, et al.
Npj Imaging|July 3, 2025
Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)Yuriko Mori, Emil Novruzov, Dominik Schmitt, et al.
BJR Case Reports|November 18, 2024
A challenging discrimination of an intensely [<sup>18</sup>F]PSMA-1007-avid solitary lesion at the skull base in a patient with biochemical recurrence of prostate cancerEmil Novruzov, Günter Niegisch, David Pauck, et al.
EJNMMI Reports|August 17, 2025
Inter-reader agreement and additive benefit of SPECT or SPECT/CT modality with [<sup>99m</sup>Tc]Tc-pertechnetate scintigraphy imaging for the assessment of thyroid nodules in a tertiary care centerEmil Novruzov, Dominik Schmitt, Katalin Mattes-György, et al.
Seminars in Nuclear Medicine|December 27, 2025
Current status of FAP therapy in solid tumorsSophie C Siegmund, Emil Novruzov, Eduards Mamlins, et al.
Cancers|October 13, 2021
FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?Katharina Dendl, Stefan A Koerber, Clemens Kratochwil, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
PET Clinics|April 7, 2023
The Diagnostic Value of Fibroblast Activation Protein Imaging in Hepatocellular Carcinoma and Cholangiocellular CarcinomaEmil Novruzov, Yuriko Mori, Fuad Novruzov
PET Clinics|April 29, 2025
Applications of Fibroblast Activation Protein Inhibitor-PET in Interventional OncologyYuriko Mori, Emil Novruzov, Frederik L Giesel, et al.
Seminars in Nuclear Medicine|July 19, 2025
The Clinical Impact of FAPI PET Imaging: HCC, CCC, CUP & Peritoneal CarcinomaEmil Novruzov, Eduards Mamlins, Yuriko Mori, et al.
Hellenic Journal of Nuclear Medicine|April 19, 2026
An auxiliary <sup>18</sup>F-FDG uptake pattern clarifying equivocal adrenal gland mass after dual-tracer imaging with <sup>123</sup>I-mIBG SPECT/CT and <sup>18</sup>F-FDG PET/CTEmil Novruzov, Sandra Jaschinski, Irene Esposito, et al.
Seminars in Nuclear Medicine|July 8, 2022
A Role of Non-FDG Tracers in Lung Cancer?Emil Novruzov, Yuriko Mori, Christina Antke, et al.
Npj Imaging|July 3, 2025
Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)Yuriko Mori, Emil Novruzov, Dominik Schmitt, et al.
BJR Case Reports|November 18, 2024
A challenging discrimination of an intensely [<sup>18</sup>F]PSMA-1007-avid solitary lesion at the skull base in a patient with biochemical recurrence of prostate cancerEmil Novruzov, Günter Niegisch, David Pauck, et al.
EJNMMI Reports|August 17, 2025
Inter-reader agreement and additive benefit of SPECT or SPECT/CT modality with [<sup>99m</sup>Tc]Tc-pertechnetate scintigraphy imaging for the assessment of thyroid nodules in a tertiary care centerEmil Novruzov, Dominik Schmitt, Katalin Mattes-György, et al.
Seminars in Nuclear Medicine|December 27, 2025
Current status of FAP therapy in solid tumorsSophie C Siegmund, Emil Novruzov, Eduards Mamlins, et al.
Cancers|October 13, 2021
FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?Katharina Dendl, Stefan A Koerber, Clemens Kratochwil, et al.
Pageof 3